HALO Earnings Date: Nov 5, 2026 (Estimated) — Halozyme Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is HALO's next earnings date?
Halozyme Therapeutics, Inc. (HALO) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $2.30 on revenue of $490.8M.
How did HALO do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Halozyme Therapeutics, Inc. posted EPS of $2.28 versus the $1.79 estimate, a beat of 26.7%. Revenue was $481.0M against a $402.3M estimate. The stock's 1-day post-earnings move was +20.2%.
How much does HALO stock move after earnings?
HALO beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.1% (up or down) in the day after earnings.
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | 1.79 | 2.28 | +26.67% | $481.0M | ✅ Beat | +20.24% | +17.39% | +28.49% |
| 2026-05-11 | Q1 2026 | 1.51 | 1.60 | +5.96% | $376.7M | ✅ Beat | +6.81% | +1.55% | +6.16% |
| 2026-02-17 | Q4 2025 | 2.15 | -0.24 | -111.16% | $451.8M | ❌ Miss | -9.01% | -12.57% | -20.91% |
| 2025-11-03 | Q3 2025 | 1.58 | 1.72 | +8.86% | $354.3M | ✅ Beat | +2.79% | +2.73% | -2.33% |
| 2025-08-05 | Q2 2025 | 1.20 | 1.54 | +28.33% | $325.7M | ✅ Beat | +2.48% | +5.31% | +20.70% |
| 2025-05-06 | Q1 2025 | 0.94 | 1.11 | +18.09% | $264.9M | ✅ Beat | +18.12% | -15.41% | -9.82% |
| 2025-02-18 | Q4 2024 | 1.16 | 1.26 | +8.62% | $298.0M | ✅ Beat | -0.22% | +0.16% | +11.05% |
| 2024-10-31 | Q3 2024 | 0.98 | 1.27 | +29.59% | $290.1M | ✅ Beat | +13.01% | +17.96% | -3.92% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $680.8M total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| Royalty | 45.2% | $307.7M | +49.6% | $155.1M | $295.3M | $168.2M | $205.6M |
| Product | 34.4% | $234.3M | +30.7% | $86.7M | $144.1M | $154.2M | $179.3M |
| Bulk rHuPH20 | 8.8% | $59.6M | — | — | — | — | — |
| Collaborative Agreements | 6.4% | $43.7M | +13.2% | $48.4M | $75.8M | $18.6M | $38.6M |
| Upfront Fees | 5.2% | $35.5M | — | — | — | — | — |
By region
FY2018 · $150.4M total · annual
| Segment | Share | Revenue | YoY | FY2013 | FY2014 | FY2015 | FY2016 |
|---|---|---|---|---|---|---|---|
| SWITZERLAND | 73.1% | $109.9M | -7.8% | $35.2M | $42.8M | $57.1M | $93.1M |
| UNITED STATES | 26.9% | $40.5M | -79.4% | $19.0M | $31.4M | $77.1M | $52.3M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.